Home > Resources > Whitepapers > Metabolic Disease Research (CCMDR) and the Weizmann Institute of Science

Metabolic Disease Research (CCMDR) and the Weizmann Institute of Science

A research workshop dedicated to metabolic disease research, with a specific emphasis on diabetes (T1D and T2D) and obesity, was held at The University of Connecticut, Department for Cell and Genome Sciences in Farmington, Connecticut, on April 11-12, 2016. The event was co-sponsored by The Jackson Laboratory (JAX), Yale University and the University of Connecticut (UConn) and included scientists from the Weizmann Institute of Science.

Spotlight

PTC Therapeutics, Inc.

PTC is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. While PTC’s discovery programs are directed at targets in multiple therapeutic areas, PTC is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders.

OTHER WHITEPAPERS

Cell and Gene Therapy Hot Buttons Series

whitePaper | September 27, 2022

Cell and Gene Therapy (CAGT) activity has increased dramatically in recent decades, especially in Chimeric Antigen Receptor T-Cell (CAR-T) clinical trials and therapy registrations. The IQVIA CAGT Hot Buttons series covers basic concepts in CAGT for newcomers to this field.

The US Bioeconomy

whitePaper | April 14, 2022

In the nearly 50 years since the first genetic engineering experiments, the United States has become the world’s biotechnology powerhouse,

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.

Validation of ICON™ Automated Cell Counting and Viability Assay

whitePaper | August 10, 2022

Determination of cell viability and concentration using trypan blue exclusion is essential for biotherapeutic workflows, enabling optimisation of protocols, monitoring of changes to the culture environment, and selection of the best clones for culture progression.